Dymon Asia Capital (Singapore) Pte. Ltd. C4 Therapeutics, Inc. Transaction History

Dymon Asia Capital (Singapore) Pte. Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$19.99 - $33.23 $164,917 - $274,147	-8,250 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$29.39 - $46.86 $242,467 - $386,595	-8,250 Reduced 50.0%	8,250 $266,000
Q3 2021 Nov 12, 2021	BUY	$35.91 - $50.5 $285,556 - $401,576	7,952 Added 93.03%	16,500 $737,000
Q2 2021 Aug 13, 2021	BUY	$30.39 - $42.18 $259,773 - $360,554	8,548 New	8,548 $323,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $214M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Dymon Asia Capital (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

Stay updated on Dymon Asia Capital (Singapore) Pte. Ltd. with notifications on news.